AstraZeneca, BMS not pursuing merger talks: Reuters
After earlier reports that AstraZeneca and New Jersey-based competitor Bristol Myers Squibb were exploring a mega merger, sources…
GSK partner Hansoh reports another phase 3 win for priority ADC
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate (ADC) to another phase 3 win in China. Weeks after reporting…
GSK Backs Relation Therapeutics With $110M to Build Biological Data Factory
Relation Therapeutics announced a strategic research collaboration with GSK focused on generating large-scale human cellular perturbation data —…
BIOSECURE Act for UK and EU life sciences companies: navigating China–US contracting risks, James Johnston, Claire Smith
The global biotech market is moving along two conflicting paths. On the one hand, Western pharmaceutical companies are…
GSK hep B drug cures one-fifth of patients in ‘major step’
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen,…
GSK pledges £44M to UK biotech to explore fibrosis regression
GSK’s latest hepatology partnership is posing a less-asked question—how do you encourage the regression of patients’ liver fibrosis?…
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer
GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge…
AZ restarts £300M UK investment after govt boosts med spending
AstraZeneca will resume a 300 million pound ($404 million) investment program in the U.K. seven months after freezing…
FDA delays ruling on AstraZeneca drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed…
AstraZeneca, after phase 3 miss, posts data behind approval bid
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to…
AstraZeneca adds FDA cell and gene veteran—Chutes & Ladders
Welcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the…
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2
When looking out across the competitive GLP-1 landscape, AstraZeneca might not be the first Big Pharma name that…